Core Laboratories Inc. CLB
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 15.56M | 24.35M | 29.03M | 29.67M | 32.12M |
| Total Depreciation and Amortization | 14.98M | 14.85M | 14.70M | 14.65M | 14.65M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 16.39M | 8.89M | 3.41M | 7.24M | -2.38M |
| Change in Net Operating Assets | -22.24M | -19.87M | -12.80M | -14.53M | 5.31M |
| Cash from Operations | 24.69M | 28.22M | 34.34M | 37.03M | 49.70M |
| Capital Expenditure | -18.02M | -17.34M | -15.90M | -14.59M | -15.32M |
| Sale of Property, Plant, and Equipment | 3.81M | 3.89M | 3.28M | 3.02M | 3.15M |
| Cash Acquisitions | -620.00K | -620.00K | -1.24M | -1.24M | -617.00K |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 566.00K | 5.39M | 7.47M | 10.58M | 10.75M |
| Cash from Investing | -14.27M | -8.68M | -6.39M | -2.23M | -2.04M |
| Total Debt Issued | 107.00M | 104.00M | 101.00M | 48.00M | 42.00M |
| Total Debt Repaid | -109.25M | -113.63M | -110.00M | -63.00M | -67.00M |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -10.40M | -14.35M | -14.40M | -12.43M | -14.67M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -1.85M | -1.85M | -1.86M | -1.87M | -1.87M |
| Other Financing Activities | -186.00K | -2.17M | -1.97M | -1.96M | -1.96M |
| Cash from Financing | -14.68M | -27.99M | -27.23M | -31.26M | -43.51M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -4.25M | -8.45M | 712.00K | 3.55M | 4.16M |